Abstract.
Some subtropical regions with similar climatic conditions to melioidosis-endemic areas, such as southern Guangxi, may be new endemic zones for melioidosis. We retrospectively reviewed seven culture-proven melioidosis patients from October 2006 to March 2015. Their clinical characteristics, diagnosis, and treatment, and the geographical and environmental factors were analyzed. Seven male patients lived at latitudes of 21–23°N in Beihai, Nanning, Chongzuo City of the Guangxi Province. Symptom onset occurred during the rainy season. All patients had pneumonia, six patients had diabetes, five patients had a history of wounds or exposure to soil or water, and two patients had liver and spleen abscesses. Most patients were misdiagnosed before the confirmatory laboratory testing. The final diagnosis was confirmed as melioidosis by isolation of Burkholderia pseudomallei in a culture of blood or pus. The 6- to 17-month treatment included carbapenems, ceftazidime, or other antibiotics active against the organism in vitro. All patients initially appeared cured, but two subsequently had recurrent melioidosis. In non-highly endemic areas, there is often a lack of awareness of melioidosis, and this leads to misdiagnoses. Other subtropical regions with climatic conditions similar to the highly melioidosis-endemic areas such as southern Guangxi may also be melioidosis endemic.
INTRODUCTION
Melioidosis, caused by Burkholderia pseudomallei, was first described in Yangon in 1912.1 Incidence rates of B. pseudomallei are increasing in regions of Southeast Asia and Northern Australia to which it is highly endemic. In mainland China, only sporadic cases have been reported, largely because it is an underrecognized and underreported disease. Guangxi, located in southern China at a latitude of 20–26°N, has a subtropical monsoon climate. Melioidosis is a very rare but emerging disease in Guangxi. We encountered seven cases of septicemia due to melioidosis in Guangxi. This study aimed to retrospectively analyze these seven cases and to discuss the epidemiology, clinical characteristics, diagnosis, and treatment of melioidosis.
MATERIALS AND METHODS
Study subjects.
The study included seven patients with melioidosis admitted to Guangxi Medical University from October 2006 to March 2015. They were identified by repeated culture of blood, bone marrow, or pus cultures. This study was approved by the Faculty of Medicine, First Affiliated Hospital of Guangxi Medical University Ethics Committee. The identities of patients and their data remained anonymous.
Diagnosis.
Bacterial identification and bacterial antimicrobial susceptibility testing were recommended by the Clinical and Laboratory Standards Institute guidelines. Blood culture bottles were cultured in the Bact/ALERT 3D 240 automatic blood culture machine (BioMerieux, Marcy-l’Étoile, France). Bacteria were isolated with a MacConkey and blood agar plate. A VITEK-32 Compact automated identification system (BioMerieux) was used for bacterial identification and bacterial antimicrobial susceptibility testing. Pneumonia was diagnosed based on the clinical symptoms and signs (e.g., fever, cough, sputum production, shortness of breath, or pleuritic chest pain) and an abnormal chest computed tomography scan. The abscesses were diagnosed when the abdominal ultrasonogram revealed a large, well-defined hypoechoic mass lesion in the liver or spleen.
RESULTS
Epidemiology.
All patients were admitted during the rainy season from August to October. All patients lived in latitudes of 21–23°N within Beihai, Nanning, Hechi, Chongzuo City in the Guangxi Province, where the rainy season is from April to October. During the rainy season, the temperatures range from 20.0 to 33.3°C, humidity ranges from 76% to 81%, average rainfall rates are > 800 mm, and altitudes range from 12 to 177 m (Figure 1).
Figure 1.
Map of Guangxi, China, showing the geographical distribution of the seven cases of melioidosis. This figure appears in color at www.ajtmh.org.
Clinical manifestations.
All seven male patients were Guangxi natives and their ages ranged from 36 to 63 years. The infection of B. pseudomallei for all patients manifested as sepsis, with initial symptoms of chills and a high-grade fever. All patients had pneumonia, five patients had bone infection, four patients had skin and soft tissue infection, two patients had liver and spleen abscesses, and one patient developed septic shock. Three patients were known to be diabetic previously. The other three patients satisfied the international criteria for the diagnosis of diabetes. Case 4 had an increased fasting blood glucose level; however, after completing all the treatments, the blood glucose level reached normal limits (Table 1).
Table 1.
Clinical data of the seven patients
| Case no. | Age (year) | Gender | Occupation | Month of occurrence | Duration of symptoms (day) | Clinical symptoms and signs | Sites of infection | Type of exposure | Risk factors |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 52 | Male | Farmer | September | 28 | Sepsis and pneumonia | Lung, right lower leg, and ankle | Stabbed by a fish bone in the right calf and contact with soil and water | Type 2 diabetes mellitus (new diagnosis) |
| 2 | 48 | Male | Worker | August | 28 | Sepsis and pneumonia | Lung, left knee and ankle, and right knee | Skin and soft tissue contusion of the left ankle and contact with soil | Type 2 diabetes mellitus |
| 3 | 36 | Male | Fisherman | September | 30 | Sepsis, pneumonia, liver and splenic abscess, and lymphadenitis | Lung, liver, spleen, pancreas, lymph node, and right upper mediastinum | Stabbed by a fish and contact with water | Kidney calculi and type 2 diabetes mellitus |
| 4 | 43 | Male | Farmer | October | 34 | Sepsis and pneumonia | Lung, right temporal fossa, parotid gland, nasopharynx, right parietal wall, sphenoid, ethmoid, right facial area, and right lower extremity | Contact with soil and water | No risk factors |
| 5 | 63 | Male | Unemployed | October | 30 | Sepsis and pneumonia | Lung and left ankle joint | Unknown | Age ≥ 50 years, type 2 diabetes mellitus (new diagnosis), and kidney calculi |
| 6 | 47 | Male | Government staff member | October | 30 | Sepsis, pneumonia, liver and splenic abscess, and urinary tract infections | Lung, liver, spleen, and right ankle joint | Unknown | Type 2 diabetes mellitus |
| 7 | 45 | Male | Farmer | September | 30 | Sepsis, pneumonia, and lymphadenitis | Lung, lymph node, right arm, and upper tibia | Contact with soil and water | Type 2 diabetes mellitus (new diagnosis) |
Results of the blood culture and antibiotic susceptibility testing.
All patients in our study underwent a blood culture within the first 1–3 hours of admission. Of the seven patients, five were blood culture positive, three were pus culture positive, one was bone marrow culture positive, and two were both blood and pus culture positive for B. pseudomallei. All B. pseudomallei isolates were sensitive to trimethoprim–sulfamethoxazole, levofloxacin, carbapenem, and β-lactam + β-lactamase inhibitors and they were resistant to gentamicin, amikacin, and aztreonam.
Treatment and outcome.
All patients had a high-grade fever, and the empirical treatment comprised imipenem, meropenem, vancomycin, ceftazidime, cefoperazone/sulbactam, or piperacillin–tazobactam. Treatment of melioidosis included intravenous and oral therapy. Carbapenems (either meropenem or imipenem), ceftazidime, cefoperazone/sulbactam, or levofloxacin was used based on the results of the antibiotic susceptibility tests. The duration of intravenous antimicrobial treatment, until the clinical effects were observed, ranged from 28 to 34 days. Once the patients showed no fever for 48 hours and had a negative repeat blood culture for seven consecutive days, intravenous therapy was changed to oral therapy. Trimethoprim–sulfamethoxazole was commonly used as oral therapy, either alone or in combination with amoxicillin/clavulanic acid. The duration of oral therapy ranged from 5 to 10 months (average, 6 months). All patients were given intensive insulin therapy and four patients underwent surgical drainage of abscesses. The total duration of treatment was 6–17 months (average, 7 months), and all patients initially recovered clinically. The longest treatment course in our group was 17 months because of the patient’s serious condition, premature withdrawal of drugs, and poor glucose control. Patients were generally reviewed at monthly infectious disease outpatient visits until completion of eradication therapy. However, two patients had subsequent culture-positive recurrence; they presented with chills, fever, and skin and soft tissue abscesses due to the premature withdrawal of drugs after hospital discharge. After reinitiating the same antimicrobial treatment, these two patients were cured. All patients were followed after discharge, and there has been no further recurrence till date (Table 2).
Table 2.
Treatment of the seven patients
| Case no. | Primary diagnosis | Initial treatment | Time to diagnosis of melioidosis | Intravenous treatment and time | Oral treatment and time | Time to recurrence |
|---|---|---|---|---|---|---|
| 1 | Sepsis, pneumonia, and septic shock | Meropenem plus vancomycin | 5 days after admission | Imipenem for 14 days and ceftazidime for 14 days | Trimethoprim–sulfamethoxazole for 6 months | None |
| 2 | Soft tissue infection of the right lower extremity and type 2 diabetes mellitus | Cefoperazone/sulbactam plus clindamycin | 6 days after admission | Imipenem for 28 days | Trimethoprim–sulfamethoxazole for 5 months | None |
| 3 | Pulmonary tuberculosis | Ceftazidime plus clindamycin | 9 days after admission | Ceftazidime for 30 days | Trimethoprim–sulfamethoxazole for 1 month | 2 months after withdrawal of drugs |
| 4 | Encephalitis | Ceftazidime plus clindamycin | 17 days after admission | Cefoperazone/sulbactam plus levofloxacin for 34 days | Trimethoprim–sulfamethoxazole for 6 months | None |
| 5 | Pneumonia and type 2 diabetes mellitus | Vancomycin plus piperacillin/tazobactam | 14 days after admission | Ceftazidime for 30 days | Trimethoprim–sulfamethoxazole for 6 months | None |
| 6 | Septicemic melioidosis, pneumonia, and type 2 diabetes mellitus | Imipenem plus ceftazidime | The day of admission | Imipenem plus ceftazidime for 30 days | Trimethoprim–sulfamethoxazole plus amoxicillin/clavulanic acid for 6 months | None |
| 7 | Severe pneumonia, sepsis, type 1 respiratory failure, and type 2 diabetes mellitus | Meropenem plus vancomycin | 5 days after admission | Meropenem plus ceftazidime for 30 days | Trimethoprim–sulfamethoxazole plus for 2 months | 2 months after withdrawal of drugs |
DISCUSSION
Melioidosis is endemic in the tropical areas of the world.2 Melioidosis-endemic regions have tropical monsoon climates and abundant rainfall. During the rainy season, the average rainfall rates range from 800 to 1,712.7 mm, temperatures range from 26.3 to 39.2°C, humidity ranges from 77.3% to 88.5%, and average altitudes range from 12 to 177 m.2–4 In endemic areas, melioidosis mainly occurs in the wet season. Burkholderia pseudomallei thrive in soil, surface water, or other natural environments and are distributed in the environment during rainfall.5 Guangxi is located in southern China and has a subtropical monsoon climate. Fifteen years ago, in Nanning, Beihai, Chongzuo, and other cities at latitudes of 21–23°N within the southern Guangxi province, a number of epidemiological studies showed that B. pseudomallei was isolated from animals and soils, and antibodies to B. pseudomallei were detected in humans, indicating that natural B. pseudomallei strains were present in Guangxi.6 However, it was not until 2010 that cases of melioidosis in humans were reported.7 The seven patients in our study lived at latitudes of 21–23°N in Beihai, Chongzuo, and Nanning City in the Guangxi Province. They had never traveled outside of Guangxi, so the infections were considered to have been acquired locally. The geography, climate, environment, rainfall, soil, and other factors from the municipalities are similar to those of areas where melioidosis is endemic.8,9
Melioidosis is usually acquired through skin abrasions or wounds, or inhalation, but zoonotic and person-to-person spread is uncommon.10 Melioidosis is more common in men; the susceptible population includes farmers, fishermen, and outdoor workers, especially those with diabetes, chronic lung disease, chronic kidney disease, long-term steroids use, and people older than 50 years.11 Among these known risk factors of melioidosis, diabetes is the most significant.12–16 All patients in our study were men and two patients were ≥ 50 years; in addition, most of them were farmers or fishermen, had a history of wounds or exposure to soil or water, and had type 2 diabetes mellitus or other underlying diseases. Thus, the seven patients from the subtropical region of southern Guangxi presented with similar onset seasons, risk factors, and possible infection routes as cases in other melioidosis-endemic regions.
Melioidosis is readily misdiagnosed in non-highly endemic areas because of a lack of familiarity with its clinical features. The highly variable manifestations of melioidosis make the diagnosis impossible without confirmatory laboratory testing. In our study, six patients were misdiagnosed. Only one patient was diagnosed as having melioidosis, as he was blood culture positive for B. pseudomallei and treated at Beihai People’s Hospital before being transferred to our hospital. Their clinical manifestations of anemia, weight loss, a severe systemic inflammatory response, and multisite abscess formation are characteristic of septicemic melioidosis. Abscesses were also identified in the bones, joints, pancreas, parotid gland, and other organs; we also noticed that the pus had a distinctive earthy and musty odor, which is uncommon in other pathogenic infections.
Current international treatment guidelines for melioidosis are usually divided into two phases: intravenous therapy is given for 10–14 days and oral therapy is administered for 3–6 months. Ceftazidime or a carbapenem (either imipenem or meropenem) is the first-line intravenous therapy; trimethoprim/sulfamethoxazole and co-amoxiclav are preferred for oral therapy.17,18 We note that some antimicrobial prescriptions such as a combination of cefoperazone/sulbactam plus levofloxacin (case no. 4) and a combination of ceftazidime plus carbapenem (case nos. 6 and 7) were not recommended as antimicrobial regimens for melioidosis, and there is no evidence to support such prescriptions. In addition, studies reported in the literature have recommended that early generation β-lactams, aminoglycosides, macrolides, and fluoroquinolones should not be used for treating melioidosis because of the high failure rate.18,19 Information and standard guidelines for the management of melioidosis need to be provided to all health-care workers in China and nonendemic areas for melioidosis. However, patients treated according to these guidelines still have high mortality and relapse rates, particularly in those with poor drug adherence.13–16 Extended periods of treatment may be needed to achieve cure and prevent recurrent infection. The median duration of intravenous therapy for patients in Northern Australia is now approximately 4 weeks and this may need to be extended to 8 weeks followed by 6 months of oral therapy for severe infections.20 The durations of intravenous and oral therapy in our study were longer than those recommended in the current international guidelines. Compared with the high mortality in Thailand, Australia, Singapore, and Malaysia,13–16 our study had a low mortality (0%; 7/7). This could be due to the small sample size, along with the facts that all patients had subacute presentations (duration of symptoms before presentation > 7 days), only one patient had septic shock on clinical presentation, and durations of intravenous and oral therapy were longer.
In summary, in nonendemic areas, there is often a lack of awareness about melioidosis. This leads to misdiagnoses, which can have fatal consequences. In our study, the epidemiology and clinical characteristics of melioidosis observed from the Guangxi region of southern China, a subtropical region, are very important for raising awareness of melioidosis. The pathogenic features, clinical characteristics, drug sensitivity results, and the geography, climate, environment, soil, rainfall, and other factors associated with melioidosis in Guangxi are very similar to those of known endemic regions. Some other subtropical regions with similar climatic conditions to melioidosis-endemic areas such as southern Guangxi may be melioidosis endemic.
Acknowledgments:
We thank Zhenbo Feng, Professor of Pathology, Department of Pathology, First Affiliated Hospital of Guangxi Medical University.
REFERENCES
- 1.Whitmore A, Krishnaswami CS, 1912. An account of the discovery of a hitherto undescribed infective disease occurring among the population of Rangoon. Ind Med Gaz 47: 262–267. [PMC free article] [PubMed] [Google Scholar]
- 2.Brilhante RS, et al. 2012. Clinical-epidemiological feautures of 13 cases of melioidosis in Brazil. J Clin Microbiol 50: 3349–3352. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Liu X, Pang L, Sim SH, Goh KT, Ravikumar S, Win MS, Tan G, Cook AR, Fisher D, Chai LY, 2015. Association of melioidosis incidence with rainfall and humidity, Singapore, 2003–2012. Emerg Infect Dis 21: 159–162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Parameswaran U, Baird RW, Ward LM, Currie BJ, 2012. Melioidosis at Royal Darwin Hospital in the big 2009–2010 wet season: comparison with the preceding 20 years. Med J Aust 196: 345–348. [DOI] [PubMed] [Google Scholar]
- 5.Raja NS, Scarsbrook C, 2016. Burkholderia pseudomallei causing bone and joint infections: a clinical update. Infect Dis Ther 5: 17–29. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Ysng S, 2000. Melioidosis research in China. Acta Trop 77: 157–165. [DOI] [PubMed] [Google Scholar]
- 7.Liu GN, Yang ML, Deng JM, Zhong XL, Zhang JQ, Jing B, 2010. Clinical manifestations of three cases with melioidosis [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi 33: 422–426. [PubMed] [Google Scholar]
- 8.Kaestli M, Mayo M, Harrington G, Harrington G, Ward L, Watt F, Hill JV, Cheng AC, Currie BJ, 2009. Landscape changes influence the occurrence of the melioidosis bacterium Burkholderia pseudomallei in soil in northern Australia. PLoS Negl Trop Dis 3: e364. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Limmathurotsakul D, Wuthiekanun V, Chantratita N, Wongsuvan G, Amornchai P, Day NP, Peacock SJ, 2010. Burkholderia pseudomallei is spatially distributed in soil in northeast Thailand. PLoS Negl Trop Dis 4: e694. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Dan M, 2015. Melioidosis in travelers: review of the literature. J Travel Med 22: 410–414. [DOI] [PubMed] [Google Scholar]
- 11.Currie BJ, Ward L, Cheng AC, 2010. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 4: e900. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Currie BJ, Ward L, Cheng AC, 2010. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 4: e900. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Limmathurotsakul D, Chaowagul W, Chierakul W, Stepniewska K, Maharjan B, Wuthiekanun V, White NJ, Day NP, Peacock SJ, 2006. Risk factors for recurrent melioidosis in northeast Thailand. Clin Infect Dis 43: 979–986. [DOI] [PubMed] [Google Scholar]
- 14.Malczewski AB, Oman KM, Norton RE, Ketheesan N, 2005. Clinical presentation of melioidosis in Queensland, Australia. Trans R Soc Trop Med Hyg 99: 856–860. [DOI] [PubMed] [Google Scholar]
- 15.Lo TJ, Ang LW, James L, Goh KT, 2009. Melioidosis in a tropical city state, Singapore. Emerg Infect Dis 15: 1645–1647. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Puthucheary SD, Parasakthi N, Lee MK, 1992. Septicaemic melioidosis: a review of 50 cases from Malaysia. Trans R Soc Trop Med Hyg 86: 683–685. [DOI] [PubMed] [Google Scholar]
- 17.Limmathurotsakul D, Peacock SJ, 2011. Melioidosis: a clinical overview. Br Med Bull 99: 125–139. [DOI] [PubMed] [Google Scholar]
- 18.Lipsitz R, Garges S, Aurigemma R, Baccam P, Blaney DD, Cheng AC, 2012. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. Emerg Infect Dis 18: e2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Dance D, 2014. Treatment and prophylaxis of melioidosis. Int J Antimicrob Agents 43: 310–318. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Currie BJ, 2015. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Semin Respir Crit Care Med 36: 111–125. [DOI] [PubMed] [Google Scholar]

